Crispr Therapeutics AG (CRSP)

[jondoeuk]

This publication includes information on the company's development of proprietary small Cas9 variants which may allow for more efficient delivery in vivo using viral delivery vehicles. They expect to move multiple programs (a number of which are partnered) utilising in vivo approaches (both viral and non-viral) into the clinic in the next 18 to 24 months https://www.nature.com/articles/s41467-021-24454-5